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Aim The aim of the study was to compare the functional and structural properties of the motor protein,
myosin, and isolated myocyte contractility in heart muscle excised from hypertrophic cardiomyopathy
patients by surgical myectomy with explanted failing heart and non-failing donor heart muscle.
Methods Myosin was isolated and studied using an in vitromotility assay. The distribution of myosin light
chain-1 isoforms was measured by two-dimensional electrophoresis. Myosin light chain-2 phosphoryl-
ation was measured by sodium dodecyl sulphate–polyacrylamide gel electrophoresis using Pro-Q
Diamond phosphoprotein stain.
Results The fraction of actin ﬁlaments moving when powered by myectomy myosin was 21% less than
with donor myosin (P ¼ 0.006), whereas the sliding speed was not different (0.310+0.034 for myect-
omy myosin vs. 0.305+0.019 mm/s for donor myosin in six paired experiments). Failing heart myosin
showed 18% reduced motility. One myectomy myosin sample produced a consistently higher sliding
speed than donor heart myosin and was identiﬁed with a disease-causing heavy chain mutation
(V606M). In myectomy myosin, the level of atrial light chain-1 relative to ventricular light chain-1
was 20+5% compared with 11+5% in donor heart myosin and the level of myosin light chain-2 phos-
phorylation was decreased by 30–45%. Isolated cardiomyocytes showed reduced contraction amplitude
(1.61+0.25 vs. 3.58+0.40%) and reduced relaxation rates compared with donor myocytes (TT50% ¼
0.32+0.09 vs. 0.17+0.02 s).
Conclusion Contractility in myectomy samples resembles the hypocontractile phenotype found in end-
stage failing heart muscle irrespective of the primary stimulus, and this phenotype is not a direct effect
of the hypertrophy-inducing mutation. The presence of a myosin heavy chain mutation causing hyper-
trophic cardiomyopathy can be predicted from a simple functional assay.
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1. Introduction
Hypertrophic cardiomyopathy is a primary disease of cardiac
muscle and is clinically deﬁned as a hypertrophied, non-
dilated left ventricle in the absence of any other aetiology.
It is a common cardiac disorder affecting one in 500 of the
population and is the leading cause of sudden death in the
young. It has been known for some time that hypertrophic
cardiomyopathy is usually familial and has been linked
to mutations in the contractile apparatus of cardiac
muscle. Although mutations have been identiﬁed in every
component of the muscle sarcomere, the most common
contractile protein mutations that cause hypertrophic
cardiomyopathy are in b myosin heavy chain (MYH7 gene)
and myosin-binding protein-C (MYBPC3 gene) which make
up 25 and 26% of all hypertrophic cardiomyopathy cases,
respectively.1–4
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Many mutations identiﬁed as causing hypertrophic
cardiomyopathy have been investigated with recombinant
proteins incorporating the mutation or in transgenic mouse
models. In vitro the mutations usually cause a gain in
function, with increased rate of crossbridge turnover and
increased Ca2þ sensitivity1,5–8 but this does not necessarily
translate into enhanced contractility in animal models.9,10
The mechanism relating the initial mutation to the develop-
ment of pathological hypertrophy is still not understood,11
nor do we know whether transgenic models of hypertrophic
cardiomyopathy are directly relevant to hypertrophic
cardiomyopathy as observed in human hearts.
Very few investigations have been made with heart muscle
from patients with hypertrophic cardiomyopathy.8,12,13 The
main reason for this has been the unavailability of suitable
material. Heart punch biopsies are rarely justiﬁed and
yield insufﬁcient material for extensive functional analysis.
However, a subset of hypertrophic cardiomyopathy patients
(about 25%) have left ventricular outﬂow tract obstruction
(LVOTO) caused by the contact between the mitral valve
leaﬂet and the hypertrophied interventricular septum in
systole. LVOTO is associated with an increased risk of
sudden death and therefore justiﬁes intervention.14 The sur-
gical septal myectomy operation removes 3–7 g of myocar-
dium from the interventricular septum in the region of the
obstruction15,16 and the excised muscle is a unique source
of human heart muscle with hypertrophic cardiomyopathy.
We have compared the functional and structural pro-
perties of myectomy muscle with end-stage failing and
non-failing donor heart muscle to determine the molecular
phenotype of hypertrophic cardiomyopathy muscle and
ultimately to link this to the disease-causing mutation. Our
initial studies, reported here, investigated the functional
properties of isolated myocytes and of the motor protein,
myosin, extracted from myectomy, failing and donor heart
muscle measured by in vitro motility assay. We have found
that myocytes are hypocontractile, and the fraction of
actin ﬁlaments moving when powered by myectomy
myosin is signiﬁcantly lower than the control myosin,
indicating dysfunction at the molecular level. In addition,
the expression of atrial light chain-1 (ALC-1) relative to ventri-
cular light chain-1 (VLC-1) in myectomy myosin is higher and
the level of myosin light chain-2 (MLC-2) phosphorylation is
lower. This pattern of results was found in every myectomy
sample independent of the mutation that is presumed to
initiate hypertrophy. One myosin sample showed a higher
sliding speed than donor myosin which we predicted was due
to a disease-causing mutation in myosin heavy chain (MHC)
and this was conﬁrmed by genotyping the tissue.
2. Methods
2.1 Collection and storage of human myocardium
2.1.1 Hypertrophic cardiomyopathy
Human myocardial samples were obtained from patients
with hypertrophic cardiomyopathy undergoing surgical
septal myectomy for relief of LVOTO. For in vitro motility
assay, the samples were snap-frozen in liquid nitrogen and
stored for later use. Local ethical approval was obtained
from University College London Hospitals and the Brompton,
Hareﬁeld and NHLI ethics committees for collection and use
of tissue samples. All patients had cardiac investigations,
including 12-lead ECG, chest X-ray, Holter monitor, cardio-
pulmonary exercise test, two-dimensional transthoracic
echocardiography, transoesophageal echocardiography,
cardiac catheterization, and coronary angiography (Table 1).
2.1.2 Non-failing and failing heart muscle
Tissue samples were supplied by Prof. C. Dos Remedios,
University of Sydney, Australia. Ethical approval was
obtained from the Brompton, Hareﬁeld and NHLI Research
Ethics Committee, London, and St Vincent’s Hospital,
Sydney. The investigation conformed with the principles
outlined in the Declaration of Helsinki. We studied tissue
from nine explanted hearts with end-stage heart failure
(ejection fraction ,20%) and eight non-failing donor
hearts. The donor heart tissue was obtained from hearts
where no suitable transplant recipient was found. The
patients had no history of cardiac disease, a normal
cardiac examination, normal ECG, and normal ventricular
function on echocardiography within 24 h of heart explanta-
tion. Myocardium was immediately frozen in liquid nitrogen
and stored for later analysis or stored in cardioplegic
solution for cell isolation. Clinical and functional character-
istics of these donor and failing heart samples have been
previously reported.17
2.2 Myosin extraction from human heart muscle
Fifty milligrams of human cardiac tissue were crushed using
a liquid-nitrogen-cooled percussion mortar and homogen-
ized in 0.25 mL ice-cold high salt extraction buffer
(0.3 mol/L KCl, 0.15 mol/L K2HPO4, 10 mmol/L Na4P2O7,
1 mmol/L MgCl2, 1 mmol/L MgATP, 10 mmol/L DTT, 3 mg/
mL each of protease inhibitors, chymostatin, pepstatin A,
leupeptin, and E64, pH 6.8). The homogenate was extracted
at 48C for 1 h on a rotating mixer and then centrifuged for
20 min at 337 000 g. The supernatant was collected and
diluted 20 with ice-cold 5 mmol/L DTTand allowed to pre-
cipitate on ice for 1 h. It was then spun for 20 min at 26 000
g at 48C to collect the precipitated myosin.8 The pellet
obtained was dissolved in 250 mL of resuspension buffer
(0.3 mol/L KCl, 25 mmol/L imidazole, pH 7.4, 1 mmol/L
EGTA, 4 mmol/L MgCl2, 10 mmol/L DTT, 1.4 mL each of
2.5 mg/mL chymostatin, pepstatin, leupeptin, and E64).
The concentration of myosin was determined using the Brad-
ford assay and the purity was assessed using sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE;
Figure 2). Using this method, 1 mg of myosin can be
obtained from 50 mg of tissue. Skeletal muscle actin and
human cardiac muscle tropomyosin and troponin were pre-
pared as previously described.17 The preparation of myoﬁ-
brils from human heart samples is described in the
Supplementary material.
2.3 In vitro motility assay
The in vitro motility assay technique was used to study
TRITC-phalloidin-labelled actin ﬁlaments moving over
immobilized myosin.18 Detailed protocols are provided in
Supplementary material.
2.4 Assay of myosin light chains
Light chain isoforms were analysed by two-dimensional elec-
trophoresis. Thirty micrograms of muscle homogenate were
separated by isoelectric focussing on 18-cm long, pI 4.5–5.5,
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Table 1 Patient details
Biopsy sample M1 M3 M4 M5 M7 M8
Diagnosis HCM HCM HCM HCM HCM HCM
Age 24 42 49 31 54 42
Myectomy date 23/06/04 04/08/04 04/08/04 11/08/04 22/09/04 17/11/04
Gender F M M M F M
Diagnosed 2001 2002 1994 1996 1992 1999
Family history No HCM; no SCD No HCM; no SCD Father died 58 years No HCM; no SCD; nine
siblings; negative
screen
No SCD; one sister w/
possible HCM
Mother SCD; 47 years HCM
at post-mortem
Current treatment Verapamil, amiodarone Atenolol, disopyramide Atenolol, aspirin,
disopyramide, clopidogrel,
quinine
Propanolol Atenolol, aminodarone,
frumil
Disopyramide, timolol
ECHO appearance ASH ASH Concentric LVH Mild ASH ASH ASH
MaxLVWT (mm) 27.5 23 16 20 22 23
Max. ST (mm) 27.5 23 16 20 22 23
LVEDD (mm) 43.6 42.0 39.0 44.0 34.0
LVESD (mm) 23.9 28.0 21.0 23.0 12.0
LA (mm) 45 41 48 41 43 44
FS (%) 45 33 48 46 64
SAM Complete Incomplete Complete Complete Incomplete Complete
MR Mild Mild Mild to moderate Trivial Mild Trivial
Resting LVOT
gradient
(mmHg)
86 22 (133 mmHg with GTN) 104 110 20 (stress, 190 mmHg) 93
VT on holter
monitor
VT (non- sustained) No Isolated VEs only No VT (non-sustained) No
ETT MVO2 (ml/
min/kg)
58% predicted; no
arrhythmias; ﬂat BP
20.3; 68% predicted; no
arrhythmias BP rise
11.7; 35% predicted; no
arrhythmias; ﬂat BP
62% predicted; no
arrhythmia; ﬂat BP
15.8; 77% predicted; no
arrhythmia; BP rise
15.0; 42% predicted; no
arrhythmias; BP rise
ECG SR, LVH, RA SR, LVH, RA SR, LVH SR, LVH SR, LVH, RA SR, LVH, RA
NYHA class II II–III II III III III
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Immobiline strips (GE Biosciences), and by SDS–PAGE in the
second dimension.19 The gels were stained with SYPRO
Ruby (Invitrogen).
One-dimensional SDS–PAGE gels were used to analyse the
levels of phosphorylation using the Pro-Q Diamond stain
developed by Molecular Probes (Invitrogen).20 Myoﬁbrils
or myosin (10–20 mg) was separated on 10  12 cm gels
(8–18% Polyacrylamide gradient, 1% SDS: Exelgel, GE
Biosciences). The gel was stained with Pro-Q Diamond
according to the manufacturer’s instructions and the phos-
phoprotein bands were visualized by UV transillumination
and recorded with a digital camera (Gene Genius/
CHEMI-HR16 system, Synoptics). The gel was then re-stained
with SYPRO Ruby or Coomassie Blue total protein stains. The
Pro-Q Diamond band volume from densitometric analysis was
normalized to the corresponding total protein band volume.
2.5 Isolation and characterization of
cardiomyocytes
Myocytes were isolated from fresh myectomy or transplant
tissue and analysed as described previously.21 Detailed pro-
tocols are provided in the Supplementary material.
2.6 Genotyping
Screening for mutations was performed by high-resolution
melting curve analysis on a Lightscanner (Idaho Technology,
Inc.) with LCGreen Plus dye. Genomic DNA samples
were quantitated with Nanodrop, quality-checked by gel
electrophoresis, and each exon was then PCR-ampliﬁed. To
promote heteroduplex formation, samples were subsequently
denatured by heating to 958C for 30 s and cooled to 208C.
Plates were centrifuged and immediately run on the
Lightscanner instrument according to the manufacturer’s
recommendations. Amplimers with aberrant melting curves
were then investigated by bidirectional sequencing.
3. Results
3.1 Properties of myocytes extracted from
myectomy muscle
Ventricular myocytes from myectomy samples had a varied
morphology, with some cells showing a clear rod-shaped
morphology, such as those in samples from non-failing or
failing ventricles, but others with a highly branched appear-
ance (Figure 1A). Surprisingly, contraction amplitudes in
myocytes from myectomy samples were low, or lower than
in those from failing hearts studied during the same
period, and relaxation was more impaired. Figure 1B com-
pares myocytes at 2 mmol/L Ca2þ, where amplitude was
signiﬁcantly lower in myectomy samples than in failing.
Relaxation had a strong tendency to be slower (Figure 1)
and was certainly more variable (comparison of variances
P , 0.001, comparison of means with Welch’s correction
for unequal variances, P ¼ 0.058). Relaxation times for myo-
cytes from failing heart shown here were similar to those
previously described from this laboratory, where relaxation
times were signiﬁcantly longer than those for non-failing
hearts.24 At 4 mmol/L Ca2þ, the amplitude difference
between myectomy and failing myocytes was reduced
(% shortening: myectomy 2.83+0.41%, 34 cells/17 patients,
failing 3.28+0.21% 110 cells/40 patients), but the
relaxation deﬁcit and high variability was maintained (R90-
: myectomy, 0.76+0.11 s, failing, 0.51+0.02 s, compari-
son of variances P , 0.001, comparison of means with
Welch’s correction for unequal variances, P , 0.05).
3.2 Altered motility function of myectomy myosin
We studied myosin in six heart muscle samples from patients
with hypertrophic obstructive cardiomyopathy (HOCM)
undergoing septal myectomy (M) and compared these with
myosin from donor heart left ventricle muscle (N). Table 1
shows the clinical details of the HOCM patients. For func-
tional studies, myosin was extracted from 50 mg samples
of frozen heart muscle by a method based on Palmiter
et al.8 (Figure 2). In vitro motility assay using freshly pre-
pared myectomy myosin showed that TRITC-phalloidin-
labelled actin ﬁlaments moved at a mean speed of 0.310+
0.034 mm/s at 308C. Myectomy muscle sliding speed was
not signiﬁcantly different from the donor heart controls
(0.305+0.019 mm/s). Comparison of the fraction of actin
ﬁlaments that were motile showed that all of the myectomy
myosin muscle samples produced a 21% lower fraction
motile than the donor control heart myosin [0.54+0.03 for
myectomy myosin compared with 0.69+0.4 for control,
P, 0.001, n ¼ 20 (four measurements each from ﬁve
paired myosin preparations); see Figure 3A and B].
We also compared the donor myosin (N) with myosin from
end-stage failing heart muscle (F) using the same preparation
method. The fraction of ﬁlaments moving was 15% lower in
the failing heart muscle (donor, 0.73+0.02; failing, 0.63+
0.03, P ¼ 0.0002) and the sliding speed was 11% lower and
this difference was also signiﬁcant (Figure 3 C and D).
The addition of 50 mmol/L human cardiac tropomyosin
had very little effect on the fraction of ﬁlaments motile
or ﬁlament sliding speed. In the presence of 40 nmol/L
human cardiac troponin, the motility of thin ﬁlaments
reconstituted with 10 nmol/L TRITC-F-actin and 50 nmol/L
tropomyosin was regulated by Ca2þ (Figure 4). At activating
Ca2þ concentrations, the fraction of ﬁlaments motile was
slightly higher for pure actin, 0.76+0.04 for donor control
myosin, and 0.61+0.09 for myectomy myosin. The lower
fraction motile of myectomy myosin is thus still observed
in fully reconstituted thin ﬁlaments. As previously
observed,22,23 the sliding speed of Ca2þ-activated thin
ﬁlaments was greater than that of pure actin ﬁlaments, by
10% for donor myosin and by 36% for myectomy myosin. In
relaxing conditions (pCa9), thin ﬁlament motility was
switched off with both myectomy and donor heart myosin.
An exception to this pattern was myosin from myectomy
sample M5 which showed no relaxation in this experiment:
in fact, the fraction of thin ﬁlaments motile was greater at
pCa9 than pCa5. The myosin preparations were too unstable
to permit determination of Ca2þ dose–response curves.
As impaired relaxation in in vitro motility assays is a
feature of many mutations that are associated with hyper-
trophic cardiomyopathy, we examined M5 myosin further
to determine whether it exhibited other characteristics in
common with hypertrophic cardiomyopathy-inducing
mutations (Table 2). In three series of paired comparisons
with N6, M5 showed a consistently higher sliding speed
ranging from 18 to 60% greater than N6 and observable
with pure actin, actin–tropomyosin, and in fully reconsti-
tuted thin ﬁlaments at pCa5. Relaxation was also less
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complete in M5 compared with N6: at pCa9 sliding speed was
faster and the fraction of ﬁlaments motile was greater for M5
myosin. All these measurements indicate a hypercontractile
phenotype for M5 myosin.
3.3 Modiﬁcations to myosin light chains
We investigated the myosin light chains in our myectomy
samples. It has been reported that ALC-1 is re-expressed in
the ventricles of patients with heart failure or hypertrophy
related to pressure overload. Myosin light chains were
detected in muscle myoﬁbrils by two-dimensional electro-
phoresis (2DE) and quantiﬁed. Compared with VLC-1,
human ALC-1 has a calculated pI 0.05 units less and a mol-
ecular weight 368 Da more and thus should appear above
and to the left of VLC-1. ALC-1 was found to be present as
a small proportion of VLC-1 in all samples tested
(Figure 5). On an average, the myectomy samples contained
twice as much ALC-1 as the donor control group.
Multiple spots corresponding to phosphorylated and
unphosphorylated MLC-2 isoforms were observed by 2DE.
However, the Pro-Q Diamond phosphoprotein stain was not
sensitive enough to identify which spots were phosphory-
lated, therefore phosphorylation of MLC-2 was measured
Figure 1 Contraction of isolated myocytes from myectomy muscle. (A) Two ventricular myocytes from myectomy samples, showing branched appearance, com-
pared with the more usual rod-shaped appearance of a ventricular myocyte from failing heart. (B) Contraction amplitude (% shortening) and time-to-50% relax-
ation of ventricular myocytes from myectomy (21 myocytes/10 hearts) and failing (41 myocytes/16 hearts) samples. #P , 0.001, variances signiﬁcantly different;
***P , 0.001, means signiﬁcantly different.
Figure 2 Isolation of myosin from human heart muscle. SDS–PAGE of (A) high
salt extract of muscle myoﬁbrils, (B) supernatant containing myosin and
troponin–tropomyosin after ultracentrifugation, and (C) pure myosin sedi-
mented at low salt concentration.
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by one-dimensional SDS–PAGE. In muscle myoﬁbrils, the
main phosphorylated proteins were myosin-binding
protein C (MyBP-C), troponin T, troponin I, and MLC-2
(Figure 6A). The level of phosphorylation, based on the
Pro-Q Diamond:Coomassie blue ratio (Q/C), of all these pro-
teins was less in the myectomy samples. The average Q/C of
MLC-2 in myectomy samples was 56% of the level in the
donor heart myoﬁbrils (Figure 6B). We can quantify this
difference on the basis of a linear relationship between
phosphorylation and Q/C as previously demonstrated for
troponin I phosphorylation,17 taking into account the non-
speciﬁc labelling of unphosphorylated protein by Pro-Q
Diamond (10% of the non-failing signal for MLC-2). On this
basis, the level of MLC-2 phosphorylation in myectomy
muscle is 51% of phosphorylation in donor heart. In the
puriﬁed myosin samples that were used for in vitro motility
measurements, the level of MLC-2 phosphorylation was
similarly reduced, by an average of 34% (Figure 7).
An approximate level of phosphorylation could be calcu-
lated from the myoﬁbril gels by comparison with troponin I
in donor control, whose phosphorylation level was previously
measured as 2.1 mol Pi/mol;17 we estimated that the MLC-2
phosphorylation level was 0.32 mol Pi/mol in donor heart
myoﬁbrils.
3.4 Genotyping of myectomy samples
The full MYH7 coding sequence for each patient was
screened for mutations by ampliﬁcation and analysis of all
exons from paired genomic DNA samples; amplimers with
aberrant melting curves were then investigated by bidirec-
tional sequencing. Genomic DNA samples from M3, M4, M7,
M8, and M10 revealed no MYH7 mutations, but mutations
were detected in M1 and M5. Patient M1 was heterozygous
for a G.A transition in exon 19, encoding the known
hypertrophic cardiomyopathy-causing missense mutation
Arg719Gln. Patient M5 was heterozygous for a G.A transition
in exon 16, encoding the known hypertrophic cardiomyopathy-
causing missense mutation Val606Met.
Figure 3 In vitro motility of human cardiac myosin with rabbit skeletal muscle actin. Actin ﬁlament motility was measured at 308C in dual-chamber motility
cells containing immobilized donor and myectomy or failing heart myosin pairs as indicated. (A, B) Myosin from ﬁve myectomy samples (M1, M3, M4, M5, M7,
black bars) was compared with myosin from donor muscle samples (N6 or N7, grey bars) in paired assays. Movement was analysed to yield the sliding speed
(A) and the fraction of ﬁlaments that were moving (B). There was no systematic difference in sliding speed (mean sliding speed myectomy myosin was 94+
0.07% of donor P ¼ 0.44), but the fraction of ﬁlaments motile was always lower with myectomy myosin (mean fraction myectomy myosin motile was
79+0.03% of donor, P ¼ 0.004). (C, D) Myosin from failing heart muscle (FA, FB, FC, FD, FE, black bars) was compared with myosin from donor muscle (NA,
NB, NC, ND, NE, grey bars) in paired assays. Movement was analysed to yield the sliding speed (C) and the fraction of ﬁlaments that were moving (D).
Sliding speed was slightly reduced in failing heart myosin (mean sliding speed failing myosin was 89+0.03% of donor, P ¼ 0.004) and the fraction of ﬁlaments
motile was also lower (mean fraction failing myosin motile was 82+ 0.04% of donor, P ¼ 0.026).
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4. Discussion
4.1 Myocytes from myectomy samples show
functional impairment
Although myectomy patients in the cohort studied were not
exhibiting symptoms of end-stage failure, myocytes isolated
from these hearts showed functional deﬁcits similar to, and
in some conditions greater than, those from patients
explanted for end-stage idiopathic or dilated cardiomyo-
pathy. Depression of contraction at physiological Ca2þ con-
centrations was more pronounced in myectomy-derived
myocytes than in failing, and became equivalent to (but
not better than) failing as Ca2þ concentration was raised.
Similarly, slow relaxation was more evident in myectomy-
derived myocytes than failing, which in turn were slower
than those from non-failing donor heart. Here we described
characteristics of a large population of both myectomy and
transplant subjects, and it is notable that variances were
signiﬁcantly higher in the myectomy population. This is
likely due to different effects of various mutations, which
will require detailed analysis when cohorts are sufﬁcient.
However, it is clear that impairment of myocyte contraction
and relaxation is a general ﬁnding in HOCM subjects.
Table 2 M5 compared with N6
Actin sliding
speed, M5/N6
Actin–
tropomyosin
sliding speed,
M5/N6
Actin–tropomyosin–
troponin sliding
speed at pCa5,
M5/N6
Actin–tropomyosin–
troponin sliding
speed at pCa9,
M5/N6
Actin–tropomyosin–
troponin fraction
motile at pCa9,
M5/N6
Preparation 1 1.28 1.21 1.46 1.52 2.78
Preparation 2 1.44 1.18 1.43 1.32 1.01
Preparation 3 1.60 1.24 1.22 1.12 1.77
Comparison of motility parameters of non-failing heart myosin (N6) and HOCM myosin, M5. M5 has a consistently hypercontractile molecular phenotype.
Figure 5 Myosin light chain detection by two-dimensional electrophoresis. Thirty micrograms of myoﬁbrils were separated by 2D electrophoresis and stained
with SYPRO Ruby. The region of the gels showing VLC-1, ALC-1, and MLC-2 are shown. VLC-1 (MYL3-HUMAN) has a pI of 5.03 and Mr of 21 800 Da, ALC-1 (MYL4-
HUMAN) has a pI of 4.98 and Mr of 21 433 Da. ALC-1 was identiﬁed in a sample of mouse heart atrium located above and to the left of VLC-1 and was found to be
present in all samples tested but more prominent in the myectomy samples (arrow). Densitometry of ALC-1 and VLC-1 spots was performed manually and the
ratio of the two isoforms is plotted on the left. Values were quite variable with a trend towards higher ALC-1 content in the myectomy samples.
Figure 4 Ca2þ regulation of motility of reconstituted thin ﬁlaments. Thin
ﬁlaments were reconstituted with 10 nmol/L TRITC-phalloidin-actin,
50 nmol/L human cardiac tropomyosin, and 40 nmol/L human cardiac tropo-
nin. In vitro motility of reconstituted thin ﬁlaments was measured at pCa5
(black bars) and pCa9 (grey bars) in dual-chamber cells and the fraction of
ﬁlaments motile is plotted. Ca2þ regulation of motility was measured with
myosin from two donor (N) heart and ﬁve myectomy (M) muscle samples.
Only M5 showed abnormal regulation.
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Figure 6 Phosphorylation of human cardiac muscle myoﬁbrils. (A) SDS–PAGE of 10 mg myoﬁbrils extracted from donor and myectomy muscle samples, succes-
sively stained with Pro-Q Diamond to label phosphoproteins and SYPRO Ruby total protein stain. High levels of phosphorylation are detected in MyBP-C, troponin
T, troponin I, and MLC-2. (B) The level of MLC-2 phosphorylation is expressed as the ratio of Pro-Q Diamond band volume:SYPRO Ruby band volume for 12
measurements from 6 donor samples and 15 measurements from 8 myectomy samples. The mean ratios are 0.78+0.06 for donor and 0.44+ 0.03 for myectomy
samples (P , 0.0001).
Figure 7 Measurement of myosin light chain-2 phosphorylation in puriﬁed myosin. (A) SDS–PAGE of puriﬁed myosin, Coomassie Blue staining. (B) Pro-Q Diamond
phosphoprotein staining of the same gel showing MLC-2 bands only. (C) Relative MLC-2 phosphorylation levels. Method as described in Figure 6. The mean Pro-Q
Diamond band volume/Coomassie Blue band volume ratios (Q/C) are 0.20+ 0.015 (n ¼ 4) for donor and 0.14+0.016 (n ¼ 7) for myectomy samples (P ¼ 0.029).
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4.2 Myosin from myectomy muscle is functionally
abnormal
We then compared the functional and structural properties of
myosin extracted from donor heart control, end-stage failing,
and hypertrophic human heart muscle obtained from surgical
myectomy operations. Myosin could be extracted in high yield
and good purity within 3 h (Figure 2) and was stable for
around 2 h in the in vitro motility assay. The sliding speed
of 0.31–0.38 mm/s at 308C was somewhat lower than previous
measurements with human heart myosin,8,24 however we
made measurements in 50 mmol/L KCl and used silica-coated
glass rather than the more usual nitrocelluose surface.25,26
We found a pattern of abnormality in all the myectomy
myosin samples; the fraction of ﬁlaments moving measured
in the in vitro motility assay was consistently 19% lower
than donor heart myosin, whereas the sliding speed, which
is considered to be a measure of crossbridge turnover
rate,24,26 was not signiﬁcantly different (Figure 3). In order
to eliminate rigor crossbridges, which would reduce motility,
we used an afﬁnity puriﬁcation step and also blocked
damaged myosin in the motility cell with unlabelled actin in
the presence of ATP. The persistence of the lower fraction
of ﬁlaments motile compared with donor muscle myosin
when prepared and assayed simultaneously suggests that
there is a stable difference in the myectomy myosin.
We examined the level of MLC-2 phosphorylation and
found that it was signiﬁcantly less in the myectomy myosin
samples compared with donor heart myosin: 49% less in myo-
ﬁbrils and 34% less in puriﬁed myosin (Figures 6 and 7). We
also measured the relative content of ALC-1 and VLC-1 in
our myosin samples by 2D electrophoresis and observed an
increase from 11+5% ALC-1 in donor control to 20+5% in
the myectomy samples (Figure 5).
As these differences were observed in all myectomy
samples, but only two (M1, M5) carried an MYH7 mutation,
it is evident that they are common consequences of HOCM
and not directly related to disease-causing mutations in
myosin. It is unlikely that the observed changes in motility
are related to the changes seen in myosin light chains since
an increased proportion of ALC-1 should increase sliding
speed27 but no change was observed. The only recorded
effect of MLC-2 phosphorylation indicated a decrease in
Ca2þ sensitivity28 which was not measured here. Thus the
defect in myosin is likely to be due to factors that are not
related to protein isoform or phosphorylation levels.
Some fresh myectomy muscle samples from the same
source were investigated for mechanical performance. In
isolated myocytes, the contraction amplitude was reduced
and the rate of relaxation was lower than in non-failing
heart samples (Figure 1) and in muscle strips there was a
negative relationship between isometric force and stimu-
lation frequency.29 It is interesting to note that these contrac-
tility parameters are similar to those observed with
end-stage failing heart or pressure overload21,30 rather than
the hypercontractile phenotype predicted from molecular
studies of hypertrophic cardiomyopathy-causing mutations.6,8
4.3 Myosin abnormalities are similar to failing
heart myosin
Many of the differences in myectomy muscle myosin resemble
those observed in failing heart muscle. Comparison of myect-
omy myosin and failing heart myosin with donor heart by
in vitro motility assay shows a similar decrease in the fraction
of ﬁlaments moving (Figure 3). The lower MLC-2 phosphoryl-
ation level (17% in myectomy muscle compared with 32% in
non-failing) is about the same as that reported for failing
heart: 18%, compared with 40% in donor heart.31 The level
of MyBP-C phosphorylation is reduced about 50% in myectomy
muscle32 and a similarly reduced level of phosphorylation has
been observed in failing heart.33 We have also observed a low
level of MyBP-C and troponin I phosphorylation in both failing
heart17,31 and myectomy muscle samples.34 An increase in
ALC-1 content in ventricular myosin from less than 5% in
donor heart to 2–27% in hypertrophic and failing heart
muscle has been reported,27,35 comparable with our ﬁnding
of 11% in donor and 20% in myectomy muscle. We did not
examine the amount of a and bMHC isoforms present,
however an investigation by Noguchi et al.36 showed that
the in vitro motility sliding speed was not different in failing
and donor heart myosin despite a variation of the
proportion of aMHC from 0 to 13%.
As the combination of increased expression of ALC-1
and decreased phosphorylation of MLC-2, troponin I, and
MyBP-C is commonly observed in failing heart muscle,17,33,35
it appears that the contractile proteins in myectomy muscle
are modiﬁed in a similar manner to failing heart. This is
compatible with our observations that in both myocytes and
in vitro motility assays contractility is similarly dysfunctional
in myectomy and failing heart samples (Figures 1 and 3). On
the other hand, some functional changes may be different in
HOCM and failing heart; for instance, troponin from myectomy
muscle shows the same Ca2þ sensitivity as donor heart34 rather
than the increased Ca2þ sensitivity characteristic of failing
heart muscle that is observed both by in vitro motility assay
and also in intact skinned muscle.17,31 The origin of the
reduced fraction motile in myectomy myosin cannot be
attributed to changes in isoforms or phosphorylation which
would inﬂuence the rate of crossbridge turnover. The fraction
motile parameter is a measure of the population of active
myosins. Inactivation may be due to a speciﬁc reason such as
a mutation, however in the case of myosin motility we
observe it in all samples, so the inactivation is probably a
result of protein damage. Damage to myosin may be due to
protein oxidation because increased oxidative stress is known
to be a feature of hypertrophy.37 In support of this idea, it
has been shown that motility and ATPase is reduced when
skeletal or smooth muscle myosin is oxidized in vitro.38,39
Clinically, all the HOCM patients had diastolic dysfunction,
but ejection fraction was usually not compromised. This
seems at odds with the molecular phenotype of the
myectomy samples, i.e. at least as severe as that observed
in end-stage failing heart. It is possible that the dysfunction
in the interventricular septum, from which our myectomy
samples were taken, is not representative of muscle in the
rest of the heart.40 The deﬁning feature of HOCM is a high
pressure difference between the aorta and ventricle due
to LVOTO caused by septal hypertrophy, therefore it is poss-
ible that local dysfunction may occur as a consequence of
pressure overload secondary to the hypertrophy triggered
by contractile protein mutations.
4.4 M5 has a disease-causing MYH7 mutation
As mutations in MYH7 (bMHC gene) account for up to 25% of
cases of hypertrophic cardiomyopathy, it was likely from the
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outset that at least one of our samples would have a disease-
causing mutation in the bMHC. M5 stood out from the other
ﬁve myectomy samples assayed as being functionally differ-
ent (Table 2). In the in vitro motility assay, ﬁlament sliding
speed was greater than the other myosin samples and relax-
ation at pCa9 was less complete. Both these properties are
characteristic of mutations that cause hypertrophic cardio-
myopathy in a variety of contractile proteins that have
been studied at the single ﬁlament level.5,6 A higher rate
of crossbridge turnover has been recognized as a feature
of the few known MHC mutations that have been studied
in muscle biopsies.8 The prediction that M5 carries a
disease-causing hypertrophic cardiomyopathy mutation was
conﬁrmed by the subsequent mutation screening, showing
that M3, M4, M7, M8, M10 are all wild-type for the whole
of MYH7 but M5 is heterozygous for Val606Met. This
mutation is one of the best documented hypertrophic
cardiomyopathy-causing alleles. We did not detect a speciﬁc
functional abnormality in M1, which also has an MYH7
mutation (Arg719Gln), however this sample was only
tested for crossbridge turnover rate using pure actin and
not for Ca2þ regulation of thin-ﬁlament motility which may
have shown changes characteristic of HCM mutations.
Previous studies by in vitro motility assay indicate HCM
mutations often cause incomplete relaxation and/or
increased Ca2þ sensitivity.5–7,27 It appears that faster cross-
bridge turnover rate is one of several diagnostic character-
istics of hypertrophic cardiomyopathy mutations.
It should be noted that the decrease in the fraction of ﬁla-
ments motile and changes in myosin light chain expression
and phosphorylation are exhibited by all samples including
M5 (Figures 3, 5, and 7). This suggests that the hypocontrac-
tile state in the interventricular septum of patients with
HOCM is not a direct effect of a hypertrophy-inducing
mutation. The connection between an altered molecular
phenotype such as that observed in M5 and the development
of pathological hypertrophy remain unknown. It is antici-
pated that further functional and structural investigation
of myectomy muscle samples, in conjunction with genotyp-
ing, will provide data that can start to explain the molecular
mechanism of hypertrophic cardiomyopathy.
Supplementary material
Supplementary material is available at Cardiovascular
Research online.
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